2525 Dupont Drive
United States - Map
Allergan, Inc. discovers, develops, and commercializes pharmaceuticals, biologics, medical devices, and over-the-counter products in the Unites States and internationally. It operates through two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including, ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, other prescription, and over-the-counter skin care products; and urology products. The Medical Devices segment provides a range of medical devices comprising breast implants for augmentation, revision, reconstructive surgery, and tissue expanders; and facial aesthetics products. The company also engages in the research and development of various products in ophthalmology, neuromodulators, migraine, urology, medical dermatology, and medical aesthetics. Allergan, Inc. markets and sells its products primarily through its subsidiaries, independent distributors, and regional sales and marketing organizations to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company primarily focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.
|Allergan Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 9; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. David E. I. Pyott ,
Chairman and Chief Exec. Officer
|Mr. Douglas S. Ingram J.D., Esq.,
|Mr. James M. Hindman ,
Chief Financial Officer and Exec. VP of Fin. & Bus. Devel.
|Mr. Raymond H. Diradoorian ,
Exec. VP of Global Technical Operations
|Dr. Scott M. Whitcup M.D.,
Chief Scientific Officer and Exec. VP of R&D
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|